PT-141 for women is an FDA-approved option for treating hypoactive sexual desire disorder (HSDD) — but only in its original injectable form. Bremelanotide, the active compound in PT-141, is a melanocortin receptor agonist that acts on brain pathways involved in arousal rather than on blood flow, which is why it’s studied specifically for low sexual desire rather than physical arousal alone. RespondWell offers a compounded PT-141 nasal spray, which uses the same active ingredient but has not itself been evaluated in the pivotal trials that led to FDA approval of the injectable product (brand name Vyleesi). That distinction matters before starting treatment, and it’s the first thing worth understanding clearly.
How Does PT-141 Work for Female Sexual Desire?
Bremelanotide works differently than the medications most people associate with sexual health. PDE5 inhibitors like tadalafil and sildenafil act peripherally, increasing blood flow to support physical arousal. PT-141 instead acts centrally, activating melanocortin-4 receptors (MC4R) in the brain that are involved in sexual desire and motivation. That mechanism is the reason it’s studied for hypoactive sexual desire disorder specifically — a condition defined by persistently low interest in sex that causes personal distress — rather than for arousal or orgasm difficulties alone. For a deeper look at the receptor biology, see our PT-141 mechanism of action guide.
Is PT-141 FDA-Approved for Women?
Yes, in one specific form. Bremelanotide, marketed as Vyleesi, received FDA approval in 2019 for premenopausal women with acquired, generalized HSDD — meaning desire that has noticeably declined from a woman’s baseline, is not limited to one partner or situation, and is not better explained by a relationship problem, another medical or psychiatric condition, or a medication side effect. The approved product is a self-administered subcutaneous autoinjector, used at least 45 minutes before anticipated sexual activity, no more than once in 24 hours and no more than 8 times per month.
RespondWell’s PT-141 nasal spray uses the same active ingredient but is a compounded formulation prepared by a pharmacy rather than an FDA-approved product in its own right. It has not gone through the same clinical trials that established Vyleesi’s approved dosing and safety profile for the injectable route. Compounded PT-141 is legal to prescribe off-label and is used clinically, but women considering it should know that the FDA approval covers the injectable product specifically, not the nasal spray formulation.
How Does Nasal Spray Dosing Differ From the Approved Injectable?
Because the nasal spray hasn’t been through the same trials, there’s no FDA label to dictate timing or frequency the way there is for Vyleesi. Instead, dosing is set by the prescribing clinician based on the compounded concentration, patient response, and clinical judgment — typically following a similar before-activity timing window as the approved product, but this can vary by provider and formulation. Our PT-141 dosage and timing guide covers the general timing principles that apply across delivery methods.
What Side Effects Should Women Expect?
In clinical trials of the approved injectable, nausea was the most common side effect, reported by a substantial share of participants, especially with the first few doses, and it tends to lessen with repeated use for many patients. Flushing, headache, and injection-site reactions were also reported. Bremelanotide can cause a transient rise in blood pressure and a temporary drop in heart rate shortly after dosing, which is why it’s generally not recommended for women with uncontrolled hypertension or known cardiovascular disease. Nasal spray formulations may carry a different side-effect profile at the local level (nasal irritation, for example) in addition to the systemic effects seen with the injectable. Some patients report the nausea is milder with nasal dosing, though this hasn’t been studied head-to-head in controlled trials. See our full PT-141 side effects breakdown for management tips.
Who Is a Candidate for PT-141, and Who Isn’t?
PT-141 is intended for women whose low desire is the primary complaint and who don’t have an obvious, more treatable cause. Before starting, it’s worth ruling out or addressing contributors like menopausal hormone changes, thyroid dysfunction, depression, relationship stress, or desire-dampening side effects from medications such as certain antidepressants. For perimenopausal and menopausal women, hormone therapy addresses a broader set of symptoms — hot flashes, sleep disruption, vaginal dryness, mood changes — and may improve desire as a secondary effect; our women’s HRT guide walks through those options. PT-141 is a more targeted tool for women whose desire has dropped independent of, or despite, those other factors being addressed. It is not intended for postmenopausal women outside of off-label use, and it isn’t a treatment for arousal or lubrication problems in isolation — those are typically addressed differently.
Frequently Asked Questions
Is PT-141 nasal spray the same as Vyleesi?
No. Both use bremelanotide as the active ingredient, but Vyleesi is the FDA-approved subcutaneous autoinjector studied in clinical trials for premenopausal HSDD. PT-141 nasal spray is a compounded, off-label formulation of the same molecule and has not been evaluated in those same trials.
How long does PT-141 take to work for women?
In studies of the injectable product, effects on desire were assessed over weeks of repeated use rather than after a single dose, though the drug itself begins acting within a few hours of dosing (which is why it’s timed before anticipated activity). Some women report noticing a difference sooner, but consistent results are typically evaluated over a full treatment cycle rather than after one use.
Can women use PT-141 alongside hormone therapy?
They can be used together in some cases, since they address different mechanisms — hormone therapy addresses hormonal symptoms broadly, while PT-141 acts on the brain’s desire pathway directly. Any combination should be reviewed by a prescribing clinician who can weigh individual health history, particularly cardiovascular risk factors.
Talk to a Clinician About PT-141
Low sexual desire that causes distress is a legitimate medical concern, not something women have to accept as a fixed part of aging or stress. If you think PT-141 might be worth exploring, RespondWell’s clinicians can review your history, discuss whether the nasal spray or another option fits your situation, and set expectations around dosing and side effects before you start. Learn more about PT-141 at RespondWell to see current pricing and get started.